Thus, we sought in subsequent studies to assess the orthogonal evidence of LSP1 and TLR1 modifying BrCa risk through the iTME, which would provide further rationale as potential I-O therapeutic targets. This evidence concerns the gene LSP1 and invasive breast carcinoma.